MDT - Medtronic plc

NYSE - Nasdaq Real Time Price. Currency in USD
91.27
+0.53 (+0.58%)
As of 2:00PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close90.74
Open90.70
Bid91.20 x 1100
Ask91.21 x 800
Day's Range90.64 - 91.50
52 Week Range76.41 - 91.50
Volume1,927,654
Avg. Volume4,384,496
Market Cap123.371B
Beta0.75
PE Ratio (TTM)40.21
EPS (TTM)2.27
Earnings DateAug 21, 2018
Forward Dividend & Yield2.00 (2.26%)
Ex-Dividend Date2018-07-05
1y Target Est95.40
Trade prices are not sourced from all markets
  • GlaxoSmithKline’s Pharmaceuticals Segment in Q2 2018
    Market Realist6 hours ago

    GlaxoSmithKline’s Pharmaceuticals Segment in Q2 2018

    GlaxoSmithKline’s (GSK) Pharmaceuticals segment includes its HIV, respiratory, immuno-inflammation, and established products. In the second quarter, Pharmaceuticals revenue grew 1% YoY (year-over-year) to ~4.23 billion British pounds at constant exchange rates.

  • Becton, Dickinson Global Foothold Strong, Recalls Rampant
    Zacksyesterday

    Becton, Dickinson Global Foothold Strong, Recalls Rampant

    Becton, Dickinson (BDX) gains from solid global foothold in Q3; foreign exchange headwinds raise concern.

  • What Does Tandem Diabetes Care’s Valuation Trend Indicate?
    Market Realist5 days ago

    What Does Tandem Diabetes Care’s Valuation Trend Indicate?

    From $8.80 on May 8, Tandem Diabetes Care’s (TNDM) stock price steadily rose to a high of $33.44 on August 3. It recovered after that to its current level of $30.75.

  • Gauging Dentsply Sirona’s Valuation Trend and Recent Acquisitions
    Market Realist5 days ago

    Gauging Dentsply Sirona’s Valuation Trend and Recent Acquisitions

    Dentsply Sirona (XRAY) has lowered its guidance for fiscal 2018. It now expects adjusted EPS of $2–$2.15 compared to the previous estimate of $2.55–$2.65. The decrease represents Dentsply’s expectation of a decline in revenue for the remainder of 2018, driven by higher levels of inventory destocking at its dealer partners.

  • Dentsply Sirona’s Segments: Q2 2018 Performance
    Market Realist5 days ago

    Dentsply Sirona’s Segments: Q2 2018 Performance

    Since its second-quarter earnings release on July 7, Dentsply Sirona (XRAY) stock has plummeted ~20%. In this series, we’ll explore its financial performance, how its segments are performing, its recent acquisitions, its valuation metrics, and what analysts expect in the coming months. Dentsply Sirona is a leading global manufacturer of professional dental products and technologies.

  • CNBC6 days ago

    Alphabet, Apple and two other stocks to buy as the S&P nears records

    After more than six months since its last high, the S&P 500 is back on the road to records. "We think the S&P is going to breakthrough that January resistance. You want to own stocks," Ari Wald, head of technical analysis at Oppenheimer, told CNBC's " Trading Nation " on Tuesday.

  • Bloomberg6 days ago

    The $250 Biohack That’s Revolutionizing Life With Diabetes

    When her daughter, Sydney, was diagnosed with Type 1 diabetes at age 8, Kate Farnsworth stopped sleeping through the night. At 6 a.m., another alarm went off to signal the next insulin dose, but by then, Kate had usually snapped awake again already. When Sydney got home from school each afternoon, Kate was there to check her glucose level.

  • InvestorPlace8 days ago

    Mazor Robotics Is Still Expensive Despite Recent Drop

    Mazor Robotics (NASDAQ:MZOR) fell nearly 15 percent last week after the company reported second-quarter results. Mazor Robotics reported revenue of $13.2 million as customers adopted its technologies in robotic guidance systems. At 20 times sales, MZOR stock is not cheap.

  • What Analysts Recommend for Haemonetics
    Market Realist8 days ago

    What Analysts Recommend for Haemonetics

    Wall Street analysts estimate Haemonetics’s (HAE) Q1 2019 revenues to increase ~4.3% to $219.9 million as compared to $210.9 million during Q1 2018. Also, the company is expected to report a net adjusted income of ~$20.0 million during Q1 2019.

  • What Analysts Expect from Haemonetics in Q1 2019
    Market Realist8 days ago

    What Analysts Expect from Haemonetics in Q1 2019

    Haemonetics (HAE) is a leading healthcare company in blood management solutions. Its devices portfolio includes surgical and diagnostic devices as well as blood and plasma center devices. The software portfolio includes blood center software, plasma center software, and hospital software.

  • InvestorPlace8 days ago

    IntriCon Is the Best A-Rated Stock You’ve Never Heard Of

    IntriCon Corporation (NASDAQ:IIN) is a small company with big promise. Granted, its market cap is less than $500 million, so now that investors see the growth potential, the stock is getting a lot of attention from mutual funds, institutional investors and momentum traders.

  • Mazor Robotics' Q2 Revenue Declines Despite Volume Gains
    Motley Fool11 days ago

    Mazor Robotics' Q2 Revenue Declines Despite Volume Gains

    System placements grew 25%, but lower pricing terms from its commercial deal with Medtronic cause the top line to head in reverse.

  • Investopedia11 days ago

    Medical Device Stocks on the Move

    On a relative basis, the sector continues to digest its strong year-to-date gains and work off a bearish momentum divergence by consolidating above our previous price objective at 0.734. An individual name in the sector breaking out is Masimo Corporation ( MASI). It has been consolidating for the past 18 months, and this push to new all-time highs signals the resumption of its long-term uptrend.

  • What Analysts Recommend for Boston Scientific, Post-Q2 Results
    Market Realist11 days ago

    What Analysts Recommend for Boston Scientific, Post-Q2 Results

    Boston Scientific (BSX) announced its Q2 2018 results on July 25, exceeding analysts’ estimates. That day, BSX stock rose ~2.2%, while the iShares US Medical Devices ETF (IHI) rose ~1.4%. BSX comprises ~4.7% of IHI.

  • United Therapeutics (UTHR) Q2 Earnings Flat Y/Y, Shares Dip
    Zacks12 days ago

    United Therapeutics (UTHR) Q2 Earnings Flat Y/Y, Shares Dip

    United Therapeutics (UTHR) reports unimpressive second-quarter earnings. Sales rise sequentially. Shares sink 5%.

  • Why Mazor Robotics Is Tanking Today
    Motley Fool12 days ago

    Why Mazor Robotics Is Tanking Today

    Shares tumble after second-quarter results miss the mark. Here's what you need to know.

  • What DexCom Just Said About Its Future
    Motley Fool12 days ago

    What DexCom Just Said About Its Future

    Sales momentum for the maker of continuous monitors for diabetes patients could accelerate.

  • Medtronic Announces Paurvi Bhatt as President of Medtronic Foundation
    GlobeNewswire13 days ago

    Medtronic Announces Paurvi Bhatt as President of Medtronic Foundation

    August 1, 2018 - Medtronic plc (MDT), the global leader in medical technology, today announced Paurvi Bhatt as the new President of the Medtronic Foundation and Vice President of Medtronic Philanthropy. Effective immediately, Bhatt will oversee all Medtronic Foundation and Medtronic Philanthropy operations, which aim to expand access to healthcare in underserved communities around the world and support healthy communities where Medtronic`s 86,000 employees live and give. Bhatt succeeds Dr. Jacob Gayle in this leadership role, following Dr. Gayle`s transition to his new position as Vice President of Social Impact for Medtronic.

  • Abbott Laboratories’ Stock Price Performance in July
    Market Realist13 days ago

    Abbott Laboratories’ Stock Price Performance in July

    On July 24, Abbott Laboratories (ABT) ended the trading day at $64.40 per share. Currently, the stock is trading higher than its 50-day moving average of $62.45 and its 200-day moving average of $60.75.

  • Intellis™, the Next Generation Medtronic Spinal Cord Stimulator for Long-Term Management of Chronic Pain, Now Licensed in Canada
    CNW Group13 days ago

    Intellis™, the Next Generation Medtronic Spinal Cord Stimulator for Long-Term Management of Chronic Pain, Now Licensed in Canada

    Intellis™, the Next Generation Medtronic Spinal Cord Stimulator for Long-Term Management of Chronic Pain, Now Licensed in Canada

  • Why Tandem Diabetes Care Is Rallying by 11.3% Today
    Motley Fool14 days ago

    Why Tandem Diabetes Care Is Rallying by 11.3% Today

    The insulin pump maker's second-quarter financials are sparking optimism.

  • Medtronic Announces 2018 Global Champions Team
    GlobeNewswire14 days ago

    Medtronic Announces 2018 Global Champions Team

    Twenty Runners Representing 13 Countries to Participate in the Medtronic Twin Cities Marathon Weekend This October DUBLIN - July 31, 2018 - This October, 20 runners from 13 different countries around the ...

  • What to Expect for DaVita’s Q2 2018 Earnings
    Market Realist14 days ago

    What to Expect for DaVita’s Q2 2018 Earnings

    DaVita (DVA), which divides its business into two segments, DaVita Kidney Care and DaVita Medical Group, is set to release its Q2 2018 results tomorrow. Analysts expect it to post EPS of $0.97 on revenue of $2.8 billion. The chart below shows DaVita’s EPS and revenue since Q1 2017, as well as analysts’ Q2 2018 estimates.